90-Day follow-up of patients treated with drotrecogin alfa (activated) for severe sepsis: A belgian open label study

Acta Clinica Belgica

Volumn 64, Issue 1, 2009, Pages 16-22

  Decruyenaere, J ^a   De Backer, D ^b   Spapen, H ^c   Laterre, P F ^d   Raemaekers, J ^e   Rogiers, P ^f   Trine, H ^g   Sartral, M ^h   Haentjens, T ^h   Wagner, T ^h  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b ERASME HOSPITAL   (Belgium)

^c UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^d CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^e SINT AUGUSTINUS HOSPITAL   (Belgium)

^f MIDDELHEIM HOSPITAL   (Belgium)

^g Hospital de Jolimont   (Belgium)

^h LILLY DEUTSCHLAND GMBH   (Germany)

Author keywords

28 day mortality; Apache ii score; Drotrecogin alfa (activated) (daa); Intensive care unit (icu); Multiple organ dysfunction (mod); Sepsis

Indexed keywords

DROTRECOGIN; HYPERTENSIVE FACTOR;

ABDOMINAL INFECTION; ADULT; AGED; APACHE; ARTICLE; ARTIFICIAL VENTILATION; BELGIUM; BLEEDING; BLOODSTREAM INFECTION; BRAIN HEMORRHAGE; CATHETER INFECTION; CAUSE OF DEATH; CHRONIC LIVER DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COMMUNICABLE DISEASE; COMORBIDITY; CONGESTIVE CARDIOMYOPATHY; CONTINUOUS INFUSION; DEATH; DIABETES MELLITUS; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; HYPERTENSION; INTENSIVE CARE UNIT; KAPLAN MEIER METHOD; LUNG HEMORRHAGE; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; METABOLIC ACIDOSIS; MORTALITY; MULTICENTER STUDY; MULTIPLE ORGAN FAILURE; OPEN STUDY; PANCREATITIS; PHASE 4 CLINICAL TRIAL; PLEURISY; RENAL REPLACEMENT THERAPY; RESPIRATORY FAILURE; RISK BENEFIT ANALYSIS; SEPSIS; SEPTIC SHOCK; SIDE EFFECT; SKIN INFECTION; STATISTICAL ANALYSIS; SURGICAL PATIENT; THROMBOCYTE COUNT; URINARY TRACT INFECTION;

EID: 61349089148     PISSN: 00015512     EISSN: None     Source Type: Journal    
DOI: 10.1179/acb.2009.005     Document Type: Article

References (17)

1. Vincent JL, Sakr YL, Carlet J, et al: Sepsis occurrence in acutely ill patients (SOAP): Results of a large European multicenter study. AmJ Respir Crit Care Med 2003; 167:A837 (abst).
2. Davies A, Green C, Hutton J, et al. Severe sepsis: a European estimate of the burden of disease in ICU. Intensive Care Med 2001,27:S284.
3. Summary of Product Characteristics (SPC) Last revision by the CHMP in February 2006.
4. Bernard GR, Vincent JL, Laterre PF, et al, for the recombinant human activated protein c worldwide evaluation in severe sepsis (PROWESS) study group, Efficacy and safety of recombinant human Activated Protein C for severe sepsis. N Engl J Med 2001;344:699-709.
5. Dhainaut JF, Laterre PF, Janes JM, et al, Drotrecogin Alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial, Intensive Care Med 2004;29:894-903.
6. Laterre PF, Levy H, Clermont G, et al. Hospital mortality and resource use in subgroups of the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trial. Crit Care Med 2004; 32: 2207-18.
7. Dhainaut JF, Shorr AF, Macias WL, et al. Dynamic evolution of coagulopathy in the first day of severe sepsis: relationship with mortality and organ failure. Crit Care Med 2005; 33: 341-8.
8. Bernard GR, Ely EW, Wright TJ, et al. Safety and dose relationship of rhAPC on coagulopathy in severe sepsis. Crit Care Med 2001; 29(11): 2051-9.
9. Vincent JL, Moreno R, Takala J, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/ failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996;22:707-10.
10. Knaus WA, Draper EA, Wagner DP, et al. APACHE II: a severity of disease classification system. Crit Care Med 1985;13:818-29.
11. Dellinger RP, Carlet JM, Madur H, et al. Surviving Sepsis Campain guidelines for management of severe sepsis and septic shock. Crit Care Med 2004; 32: 858-73.
12. Oral Communication, Surviving Sepsis Campain guidelines for management of severe sepsis and septic shock, ISICEM, March 2006.
13. Warren BL, Eid A, Singer P, et al. High-dose Antithrombin III in severe sepsis A randomized controlled trial. JAMA 2001; 286: 1869-78.
14. Abraham E, Reinhart K, Opal S, et al. Efficacy and safety of Ti-facogin (Recombinant Tissue Factor Pathway Inhibitor) in severe sepsis. A randomized controlled trial. JAMA 2003; 290: 238-47.
15. Vincent JL, Bernard GR, Beale R, et al. Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment. Crit Care Med 2005, 33:2266-77.
16. Abraham E, Laterre PF, Garg R, et al. Drotrecogin alfa (activated) for adult patients with severe sepsis and a low risk of death. N Eng J Med 2005, 353: 1332-41.
17. Nadel S, Goldstein B, Williams MD. Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial. Lancet 2007, 369:836-43.